# A Study of Elpipodect (MK-8189) in Participants With Schizophrenia (MK-8189-014)

> **NCT05406440** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 53 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Elpipodect
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05406440
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-12
- **Primary completion:** 2023-02-24
- **Final completion:** 2023-02-24
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05406440

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05406440, "A Study of Elpipodect (MK-8189) in Participants With Schizophrenia (MK-8189-014)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05406440. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*